Lisata Therapeutics, Inc.
NasdaqCM LSTA
Lisata Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.47
-
Lisata Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.02 on December 19, 2024, which is 30.88% above the current Price to Earnings Ratio (P/E).
-
Lisata Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.56 on January 03, 2025, which is -5.77% below the current Price to Earnings Ratio (P/E).
-
Lisata Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.24.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. |
| IPO Date | March 1, 1999 |
| Location | United States |
| Headquarters | 110 Allen Road |
| Employees | 25 |
| Sector | Health Care |
| Industries | |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Past 5 years
USD 1.87
USD 4.72
USD 2.50
USD 5.56
USD 1.22
USD 0.84
USD 5.90
USD 7.84
StockViz Staff
January 15, 2025
Any question? Send us an email